MCID: GM1005

Gm1-Gangliosidosis, Type Ii

Categories: Genetic diseases, Rare diseases, Metabolic diseases, Neuronal diseases, Eye diseases, Bone diseases

Aliases & Classifications for Gm1-Gangliosidosis, Type Ii

MalaCards integrated aliases for Gm1-Gangliosidosis, Type Ii:

Name: Gm1-Gangliosidosis, Type Ii 53 13
Gm1 Gangliosidosis Type 2 49 55 28
Gangliosidosis, Generalized Gm1, Type 2 53 69
Gangliosidosis Generalized Gm1 Type 2 49 71
Gangliosidosis, Generalized Gm1, Late-Infantile Type 28
Gangliosidosis Generalized Gm1 Late Infantile Type 71
Gangliosidosis, Generalized Gm1, Juvenile Type 53
Gangliosidosis Generalized Gm1 Juvenile Type 49
Gm1-Gangliosidosis Generalized Juvenile Type 71
Gangliosidosis, Generalized Gm1, Type Ii 53
Late-Infantile Gm1 Gangliosidosis 55
Juvenile Gm1 Gangliosidosis 55
Gm1-Gangliosidosis 2 71
Gm1g2 71


Orphanet epidemiological data:

gm1 gangliosidosis type 2
Inheritance: Autosomal recessive; Prevalence: <1/1000000 (Worldwide); Age of onset: Childhood;


autosomal recessive

onset of disease 7 months to 3 years
survival to 10 years


gm1-gangliosidosis, type ii:
Inheritance autosomal recessive inheritance


Summaries for Gm1-Gangliosidosis, Type Ii

OMIM : 53 GM1-gangliosidosis type II is an autosomal recessive lysosomal storage disease characterized by slowly progressive generalized neurodegeneration and mild skeletal changes, with onset between 7 months and 3 years of age. Unlike the severe infantile type I, type II is usually not associated with macular cherry-red spots or organomegaly. Within type II, those with somewhat earlier onset and earlier death are considered to have the 'late-infantile' form, whereas those with slightly later onset and survival into late childhood are referred to as having the 'juvenile' form (Caciotti et al., 2003). However, there is no strict age marker to distinguish between these 2 type II forms. GLB1 enzyme activity in type II ranges from approximately 1 to 4% of control values (Nishimoto et al., 1991; Yoshida et al., 1991). (230600)

MalaCards based summary : Gm1-Gangliosidosis, Type Ii, also known as gm1 gangliosidosis type 2, is related to gm1-gangliosidosis, type i and lysosomal storage disease, and has symptoms including ataxia, gait disturbance and optic atrophy. An important gene associated with Gm1-Gangliosidosis, Type Ii is GLB1 (Galactosidase Beta 1). The drugs Miglustat and 1-Deoxynojirimycin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone.

UniProtKB/Swiss-Prot : 71 GM1-gangliosidosis 2: A gangliosidosis characterized by onset between ages 1 and 5. The main symptom is locomotor ataxia, ultimately leading to a state of decerebration with epileptic seizures. Patients do not display the skeletal changes associated with the infantile form, but they nonetheless excrete elevated amounts of beta-linked galactose-terminal oligosaccharides. Inheritance is autosomal recessive.

NIH Rare Diseases : 49 GM1 gangliosidosis is an inheritedlysosomal storage disorder that progressively destroys nerve cells (neurons) in the brain and spinal cord. The condition may be classified into three major types based on the general age that signs and symptoms first appear: classic infantile (type 1); juvenile (type 2); and adult onset or chronic (type 3). Although the types differ in severity, their features may overlap significantly. GM1 gangliosidosis is caused by mutations in the GLB1 gene and is inherited in an autosomal recessive manner. Treatment is currently symptomatic and supportive. Last updated: 11/17/2015

Related Diseases for Gm1-Gangliosidosis, Type Ii

Diseases in the Gangliosidosis Gm2 family:

Gm1-Gangliosidosis, Type I Gm1-Gangliosidosis, Type Ii
Gm1-Gangliosidosis, Type Iii Gm2-Gangliosidosis, Ab Variant
Gangliosidosis Gm1 Gm2 Gangliosidosis, 0 Variant
Gm2-Gangliosidosis, B, B1, Ab Variant

Diseases related to Gm1-Gangliosidosis, Type Ii via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 gm1-gangliosidosis, type i 10.4
2 lysosomal storage disease 10.1
3 blood group, i system 9.8

Symptoms & Phenotypes for Gm1-Gangliosidosis, Type Ii

Symptoms via clinical synopsis from OMIM:

Head And Neck Eyes:
optic atrophy

Neurologic Central Nervous System:
progressive psychomotor deterioration
cerebral atrophy
myoclonic seizures
spastic quadriplegia
Head And Neck Face:
normal facies

Abdomen Spleen:
no splenomegaly

Laboratory Abnormalities:
decreased beta-galactosidase activity (leukocyte, fibroblast, plasma)

Skeletal Pelvis:
coxa valga
mild flaring of iliac wings

Skeletal Spine:
mild platyspondyly

Abdomen Liver:
no hepatomegaly

sea-blue histiocyte (bone marrow)

Clinical features from OMIM:


Human phenotypes related to Gm1-Gangliosidosis, Type Ii:

31 (show all 16)
# Description HPO Frequency HPO Source Accession
1 ataxia 31 HP:0001251
2 gait disturbance 31 HP:0001288
3 optic atrophy 31 HP:0000648
4 spastic tetraplegia 31 HP:0002510
5 generalized myoclonic seizures 31 HP:0002123
6 platyspondyly 31 HP:0000926
7 coxa valga 31 HP:0002673
8 developmental stagnation 31 HP:0007281
9 progressive psychomotor deterioration 31 HP:0007272
10 ventriculomegaly 31 HP:0002119
11 abnormality of the face 31 HP:0000271
12 abnormality of the spleen 31 HP:0001743
13 abnormality of the liver 31 HP:0001392
14 cerebral atrophy 31 HP:0002059
15 sea-blue histiocytosis 31 HP:0001982
16 decreased beta-galactosidase activity 31 HP:0008166

UMLS symptoms related to Gm1-Gangliosidosis, Type Ii:

myoclonic seizures

Drugs & Therapeutics for Gm1-Gangliosidosis, Type Ii

Drugs for Gm1-Gangliosidosis, Type Ii (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Miglustat Approved Phase 4 72599-27-0 51634
1-Deoxynojirimycin Experimental Phase 4 19130-96-2 1374
3 Anti-HIV Agents Phase 4
4 Anti-Infective Agents Phase 4
5 Anti-Retroviral Agents Phase 4
6 Antiviral Agents Phase 4
7 Cardiac Glycosides Phase 4
8 Glycoside Hydrolase Inhibitors Phase 4
9 Hypoglycemic Agents Phase 4

Interventional clinical trials:

# Name Status NCT ID Phase Drugs
1 Synergistic Enteral Regimen for Treatment of the Gangliosidoses Recruiting NCT02030015 Phase 4 miglustat

Search NIH Clinical Center for Gm1-Gangliosidosis, Type Ii

Genetic Tests for Gm1-Gangliosidosis, Type Ii

Genetic tests related to Gm1-Gangliosidosis, Type Ii:

# Genetic test Affiliating Genes
1 Gm1 Gangliosidosis Type 2 28 GLB1
2 Gangliosidosis, Generalized Gm1, Late-Infantile Type 28

Anatomical Context for Gm1-Gangliosidosis, Type Ii

MalaCards organs/tissues related to Gm1-Gangliosidosis, Type Ii:

Brain, Spinal Cord, Bone, Liver, Eye, Bone Marrow, Spleen

Publications for Gm1-Gangliosidosis, Type Ii

Articles related to Gm1-Gangliosidosis, Type Ii:

# Title Authors Year
GM1 gangliosidosis type 2 in two siblings. ( 1588015 )
GM1 gangliosidosis, type 2: ocular clinicopathologic correlation. ( 6440832 )
Studies on GM1-gangliosidosis, type II. ( 4217089 )
Intrauterine detection of GM1 gangliosidosis, type 2. ( 4742246 )

Variations for Gm1-Gangliosidosis, Type Ii

UniProtKB/Swiss-Prot genetic disease variations for Gm1-Gangliosidosis, Type Ii:

71 (show all 19)
# Symbol AA change Variation ID SNP ID
1 GLB1 p.Arg49Cys VAR_003329
2 GLB1 p.Arg201Cys VAR_003332
3 GLB1 p.Arg590His VAR_008683
4 GLB1 p.Glu632Gly VAR_008686
5 GLB1 p.Arg201His VAR_013542
6 GLB1 p.Gly579Asp VAR_013555
7 GLB1 p.Arg68Trp VAR_026130
8 GLB1 p.Leu155Arg VAR_037939
9 GLB1 p.Arg68Gln VAR_062341
10 GLB1 p.Arg148Cys VAR_062346
11 GLB1 p.Leu264Ser VAR_062355
12 GLB1 p.Tyr333His VAR_062359
13 GLB1 p.Gly262Glu VAR_074057
14 GLB1 p.Phe314Leu VAR_074059
15 GLB1 p.Leu337Pro VAR_074061
16 GLB1 p.Gly414Val VAR_074062
17 GLB1 p.Lys493Asn VAR_074063
18 GLB1 p.Pro597Leu VAR_074065
19 GLB1 p.Thr600Ile VAR_074066

ClinVar genetic disease variations for Gm1-Gangliosidosis, Type Ii:

6 (show all 24)
# Gene Variation Type Significance SNP ID Assembly Location
1 GLB1 NM_000404.3(GLB1): c.518T> C (p.Leu173Pro) single nucleotide variant Likely pathogenic rs397515617 GRCh37 Chromosome 3, 33106989: 33106989
2 GLB1 NM_000404.3(GLB1): c.1004C> T (p.Ala335Val) single nucleotide variant Likely pathogenic rs398123347 GRCh37 Chromosome 3, 33087676: 33087676
3 GLB1 NM_000404.3(GLB1): c.1174_1175delCT (p.Leu392Valfs) deletion Pathogenic rs398123348 GRCh37 Chromosome 3, 33063116: 33063117
4 GLB1 NM_000404.3(GLB1): c.1310A> T (p.Asn437Ile) single nucleotide variant Likely pathogenic rs202237232 GRCh37 Chromosome 3, 33059977: 33059977
5 GLB1 NM_000404.3(GLB1): c.1456_1466dupGGTGCATATAT (p.Ile489Metfs) duplication Pathogenic rs398123349 GRCh37 Chromosome 3, 33058214: 33058224
6 GLB1 NM_000404.3(GLB1): c.171C> G (p.Tyr57Ter) single nucleotide variant Pathogenic rs398123350 GRCh37 Chromosome 3, 33114110: 33114110
7 GLB1 NM_000404.3(GLB1): c.1769G> A (p.Arg590His) single nucleotide variant Pathogenic rs398123351 GRCh37 Chromosome 3, 33038802: 33038802
8 GLB1 NM_000404.3(GLB1): c.397-1G> A single nucleotide variant Pathogenic rs398123353 GRCh37 Chromosome 3, 33109783: 33109783
9 GLB1 NM_000404.3(GLB1): c.442C> T (p.Arg148Cys) single nucleotide variant Pathogenic rs192732174 GRCh37 Chromosome 3, 33109737: 33109737
10 GLB1 NM_000404.3(GLB1): c.457+2T> C single nucleotide variant Pathogenic rs398123354 GRCh37 Chromosome 3, 33109720: 33109720
11 GLB1 NM_000404.3(GLB1): c.51dupT (p.Leu18Serfs) duplication Pathogenic rs398123356 GRCh37 Chromosome 3, 33138527: 33138527
12 GLB1 NM_000404.3(GLB1): c.75+1G> C single nucleotide variant Pathogenic rs398123358 GRCh37 Chromosome 3, 33138502: 33138502
13 GLB1 NM_000404.3(GLB1): c.901G> A (p.Ala301Thr) single nucleotide variant Likely pathogenic rs727503954 GRCh38 Chromosome 3, 33051896: 33051896
14 GLB1 NM_000404.3(GLB1): c.1077delA (p.Val360Tyrfs) deletion Pathogenic rs727503952 GRCh37 Chromosome 3, 33065809: 33065809
15 GLB1 NM_000404.3(GLB1): c.1A> C (p.Met1Leu) single nucleotide variant Likely pathogenic rs794726886 GRCh37 Chromosome 3, 33138577: 33138577
16 GLB1 NM_000404.3(GLB1): c.1768C> T (p.Arg590Cys) single nucleotide variant Pathogenic rs794727165 GRCh37 Chromosome 3, 33038803: 33038803
17 GLB1 NM_000404.3(GLB1): c.169delT (p.Tyr57Thrfs) deletion Pathogenic rs794727249 GRCh37 Chromosome 3, 33114112: 33114112
18 GLB1 NM_000404.3(GLB1): c.602G> A (p.Arg201His) single nucleotide variant Pathogenic rs189115557 GRCh37 Chromosome 3, 33099712: 33099712
19 GLB1 NM_000404.3(GLB1): c.1445G> A (p.Arg482His) single nucleotide variant Pathogenic rs72555391 GRCh37 Chromosome 3, 33058235: 33058235
20 GLB1 NM_000404.3(GLB1): c.622C> T (p.Arg208Cys) single nucleotide variant Pathogenic rs72555366 GRCh37 Chromosome 3, 33099692: 33099692
21 GLB1 NM_000404.3(GLB1): c.202C> T (p.Arg68Trp) single nucleotide variant Pathogenic rs72555370 GRCh37 Chromosome 3, 33114079: 33114079
22 GLB1 NM_000404.3(GLB1): c.176G> A (p.Arg59His) single nucleotide variant Pathogenic rs72555392 GRCh37 Chromosome 3, 33114105: 33114105
23 GLB1 NM_000404.3(GLB1): c.1733A> G (p.Lys578Arg) single nucleotide variant Pathogenic rs371582179 GRCh37 Chromosome 3, 33055549: 33055549
24 GLB1 NM_000404.3(GLB1): c.245+1G> A single nucleotide variant Likely pathogenic rs778423653 GRCh37 Chromosome 3, 33114035: 33114035

Expression for Gm1-Gangliosidosis, Type Ii

Search GEO for disease gene expression data for Gm1-Gangliosidosis, Type Ii.

Pathways for Gm1-Gangliosidosis, Type Ii

GO Terms for Gm1-Gangliosidosis, Type Ii

Sources for Gm1-Gangliosidosis, Type Ii

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
51 Novoseek
54 OMIM via Orphanet
58 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....